Balancing evidence and individualization in adjuvant CDK4/6 therapy
Transl Cancer Res
.
2025 Aug 31;14(8):4479-4481.
doi: 10.21037/tcr-2025-879.
Epub 2025 Aug 16.
Authors
Humaid O Al-Shamsi
1
2
3
,
Muharrem Oner
4
5
,
Kefah Mokbel
4
Affiliations
1
Burjeel Cancer Institute, Burjeel Medical City, Abu Dhabi, United Arab Emirates.
2
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
3
College of Medicine, Ras Al Khaimah Medical and Health Sciences University, Ras Al Khaimah, United Arab Emirates.
4
London Breast Institute, The Princess Grace Hospital, London, UK.
5
Department of Surgery, Antalya City Hospital, Antalya, Turkey.
PMID:
40950694
PMCID:
PMC12432663
DOI:
10.21037/tcr-2025-879
No abstract available
Keywords:
Breast; cancer; cyclin-dependent kinase 4 and 6 therapy (CDK4/6 therapy).
Publication types
Editorial
Comment